Screening for the early detection of ovarian cancer

David M. Robertson

    Research output: Contribution to journalArticleResearchpeer-review

    3 Citations (Scopus)


    A randomized, controlled trial was undertaken to assess the use of serum CA125 and ovarian ultrasound as diagnostic markers in the early detection of ovarian cancer. The trial consisted of 202,638 postmenopausal women who were assessed annually between 2001 and 2005. A nonscreen group and two screening groups were investigated. The screening groups included serum CA125, which was based on a rate-of-change algorithm, plus transvaginal ultrasound (in at-risk women); and an ovarian ultrasound group only, prior to clinical review and surgery. The sensitivity, specificity and positive predictive values for all primary ovarian and tubal cancers for the combined test group was 89.4, 99.8 and 43.3%, respectively, and for the ultrasound group 84.9, 98.2 and 5.3%, respectively, with a significant difference in specificity between groups. The combined test provides the requisite specificity for a screening test for ovarian cancer in postmenopausal women.

    Original languageEnglish
    Pages (from-to)347-349
    Number of pages3
    JournalWomen's Health
    Issue number4
    Publication statusPublished - 2009


    • Biomarkers
    • CA125
    • Ovarian cancer
    • Transvaginal ultrasound

    Cite this